Risky Business: Most Cancer Drugs Don't Reach the Market : c

A new analysis finds that a cancer drug tested in a phase 1 trial has about a 6% chance of eventual FDA approval, but some factors may up those odds.

Related Keywords

Japan , Japanese , Alyson Haslam , Jeff Allen , Drug Administration , International Journal Of Cancer , University Of California San Francisco , Friends Of Cancer Research , California San Francisco , Medscape Medical , International Journal , Practice Management , Hematology , Multiple Myeloma , Myeloma , Plasma Cell Myeloma , Antineoplastic Drug , Nti Cancer Agents , Evacizumab , Rlotinib , Efitinib , Matinib , Ituximab , U11248 , Unitinib , Rastuzumab , Cancer , Alignant Neoplasia , Arcinoma , Us Food And Drug Administration , Nited States Food And Drug Administration , Fda , Clinical Research , Clinical Trials , Linical Studies , Biologic Therapy , D ,